Journey Medical Corporation was incorporated in Delaware in October 2014. The company is a commercial-stage pharmaceutical company focused on marketing dermatological prescription drugs approved by the U.S. Food and Drug Administration. Its product portfolio includes a variety of marketed drugs that are commercialized through its field sales team. 

Journey Medical Corporation announced that CEO Claude Maraoui will participate in two investor conferences in September 2026. The events include the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference on September 10 and the H.C. Wainwright 28th Annual Global Investment Conference on September 14. Maraoui will present at H.C. Wainwright and hold one-on-one meetings at both conferences. Journey Medical is a commercial-stage pharmaceutical company focused on dermatological treatments.

Journey Medical

Journey Medical to Present at Two Investor Conferences in September

Journey Medical (DERM) shares rose 13.20% in intraday trading after the company reported strong second-quarter 2026 earnings results. Revenue grew 23% year-over-year to $18.5 million, driven by $8.1 million in Emrosi sales, while the GAAP net loss narrowed to $0.3 million.

Journey Medical (DERM) rises 13.20% intraday after strong Q2 2026 earnings

Journey Medical Corp reported Q2 FY26 revenue of $18.5mln, up 23% YoY, driven by strong demand for Emrosi, an oral treatment for rosacea, which generated $8.1mln in revenue. Gross margin remained stable at 67%, while GAAP net loss narrowed to $0.3mln from $3.8mln in Q2 2025. Emrosi prescriptions reached 36,000, with 5,000 in the first 6 weeks of July, indicating continued commercial momentum.

Journey Medical's Q2 Revenue Up 23% Driven by Emrosi Sales

Journey Medical's Q2 report confirms the company's thesis is on track as Emrosi launch gains traction. Despite a 13% year-to-date decline, shares have seen a 3-year gain of over +220%. The company's $190M enterprise value has made it a frustrating hold for investors.

Journey Medical Q2 Report Validates Growth Thesis Amid Emrosi Launch

Fortress Biotech, Inc. (Nasdaq: FBIO) reported net revenue of $17.4 million for the second quarter of 2023, representing <a href="https://www.fortressbiotech.com/news-media/press-releases/detail/562/fortress-biotech-reports-second-quarter-2023-financial">a 40% increase compared</a> to $12.4 million in the first quarter of 2023. The company attributed this growth to strong performance from its marketed dermatology products and continued progress in its clinical development programs. Journey Medical Corporation, a partner company of Fortress, reported total product net revenues of $17.0 million for the second quarter of 2023, reflecting <a href="https://www.fortressbiotech.com/news-media/press-releases/detail/562/fortress-biotech-reports-second-quarter-2023-financial">sequential growth from $12.2 million</a> in the first quarter. Positive topline results from two Phase 3 clinical trials of DFD-29 for papulopustular rosacea were also highlighted, with the drug <a href="https://www.fortressbiotech.com/news-media/press-releases/detail/562/fortress-biotech-reports-second-quarter-2023-financial">demonstrating statistical superiority over Oracea</a> and placebo. Fortress plans to file an NDA for DFD-29 in the second half of 2023, with <a href="https://www.fortressbiotech.com/news-media/press-releases/detail/562/fortress-biotech-reports-second-quarter-2023-financial">FDA approval expected in</a> the second half of 2024.In addition, Checkpoint Therapeutics, another partner company, submitted a Biologics License Application (BLA) for cosibelimab, an anti-PD-L1 antibody, for the treatment of advanced cutaneous squamous cell carcinoma. The FDA accepted the BLA and <a href="https://www.fortressbiotech.com/news-media/press-releases/detail/562/fortress-biotech-reports-second-quarter-2023-financial">set a PDUFA goal date</a> of January 3, 2024. Fortress also noted that <a href="https://www.fortressbiotech.com/news-media/press-releases/detail/562/fortress-biotech-reports-second-quarter-2023-financial">two additional NDAs expected to be</a> filed by the end of 2023.Despite the revenue growth, Fortress reported a net loss attributable to common stockholders of $26.8 million, or $0.24 per share, for the second quarter of 2023. On a non-GAAP basis, <a href="https://www.fortressbiotech.com/news-media/press-releases/detail/562/fortress-biotech-reports-second-quarter-2023-financial">the loss was $8.0 million</a>, or $0.07 per share. The company emphasized that its non-GAAP metrics exclude the operations of its public partner companies and focus on the performance of its core operations.Fortress Biotech continues to advance its pipeline of drug candidates across multiple therapeutic areas, including oncology, rare diseases, and gene therapy. With several late-stage clinical assets in development and anticipated regulatory milestones in the coming months, the company remains focused on <a href="https://www.fortressbiotech.com/news-media/press-releases/detail/562/fortress-biotech-reports-second-quarter-2023-financial">creating long-term value for shareholders</a> through its equity interests and royalties.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1cfa0b8ac0171002.png" alt="Fortress Biotech 2Q net revenue $18.7M">

DERM News